About ACEA Biosciences
Our mission, history, and opportunities.
Our mission, history, and opportunities.
ACEA Biosciences’ mission is to provide innovative high performance technologies that advance scientific discovery and improve healthcare.
Founded in 2002, ACEA Biosciences, Inc. is a privately owned biotechnology company that is pioneering the development and commercialization of high performance, cutting edge cell analysis instruments for life science research and clinical diagnostics.
Employing noninvasive impedance microelectrodes in automated high-throughput plate formats, our xCELLigence® Real-Time Cell Analysis (RTCA) instruments maximize the physiological relevance of data extracted from in vitro cellular assays. These instruments enable label-free, real-time monitoring of cell proliferation, cell size/morphology, cell-substrate attachment quality, and cell invasion/migration. By eliminating the time- and labor-intensive steps of traditional methods, RTCA vastly improves efficiency and overall productivity. Moreover, the flexibility, sensitivity, and reproducibility of RTCA make it a standout amongst cell-based assay platforms.
ACEA is also helping to revolutionize the field of flow cytometry by designing and producing high performance, customizable benchtop cytometers at accessible price points. By including features such as 13 fluorescence detection channels with 3 lasers, direct volumetric based cell counting, and a versatile high throughput walkaway autosampler, ACEA’s line of NovoCyte® flow cytometers is raising the bar for what is expected of benchtop machines.
xCELLigence® and NovoCyte® instruments are currently being used worldwide in academic, industrial, and hospital labs for preclinical drug discovery and development, toxicology, safety pharmacology, disease studies, clinical diagnostics, and basic research.
ACEA Biosciences®, Inc (ACEA) is founded in San Diego, California, USA. Initial efforts are focused on developing and commercializing an impedance-based system (both instrument and consumables) for label-free, real-time, quantitative analysis of cell proliferation, cell size/morphology, and cell-substrate attachment quality.
ACEA launches its first Real-Time Cell Electronic Sensing (RT-CES®) system for cell-based assays.
Roche and ACEA enter an exclusive worldwide license agreement, which lasted through 2012, for the development, supply, and distribution of ACEA’s RT-CES® system. RT-CES® is rebranded as xCELLigence® Real Time Cell Analysis (RTCA).
The first xCELLigence® RTCA system is officially launched. The xCELLigence® RTCA SP (single plate) system utilizes a 96-well electronic microtiter plate (E-Plate®).
Two new systems are launched. The xCELLigence® RTCA DP (dual purpose) system has all of the standard RTCA functionality but with the added ability to monitor cell invasion and migration in real-time using a CIM-Plate® (an electronic Boyden chamber). The xCELLigence® RTCA MP (multiple plate) system supports up to six 96-well E-Plates® which can be controlled and monitored simultaneously yet independently of one another, allowing maximal productivity for multiple users.
Two additional systems are launched. By measuring impedance on the millisecond time scale, the xCELLigence® RTCA Cardio system is able to monitor the contractile activity of beating cardiomyocytes. The xCELLigence® RTCA HT (high throughput) system employs a 384-well E-Plate® to facilitate large drug discovery and safety screening campaigns.
ACEA launches the smaller-sized RTCA iCELLigence™ system for cell quality control and assay optimization. This system utilizes the same RTCA impedance technology but uses Wi-Fi for data transfer and employs plates whose larger wells provide enough cells for complementary assays including western blotting, sequencing analyses, FACS, imaging, etc.
ACEA develops and launches the groundbreaking NovoCyte® Flow Cytometer. This bench-top cytometer offers up to 3 lasers with 13 color detection, direct volumetric-based cell counting, a flexible high throughput autosampler, and automatic cleaning/decontamination functions at an exceptional price point.
In response to the FDA CiPA initiative and the longstanding need for more predictive preclinical assays of cardiac liability, ACEA introduces its 2nd generation cardio system – the xCELLigence® RTCA CardioECR (Extra Cellular Recording). This is the first instrument to combine a high rate of impedance data acquisition (1 millisecond) with field potential measurement (10 kHz) and a pacing stimulus to enable simultaneous monitoring of cardiomyocyte contractility, viability, and electrophysiology.